Early administration of neutralizing monoclonal antibodies and post-acute sequelae of COVID-19
Early mAb therapy did not significantly alter overall PASC risk but was associated with increased autoimmune complications. These findings may highlight the need for long-term safety monitoring in future mAb trials for SARS-CoV-2.
Authors
- Barnaby Edward Young (ORCID: https://orcid.org/0000-0003-1010-2230)
- Huei Xin Lou
- Shawn Vasoo (ORCID: https://orcid.org/0000-0001-7812-9881)
- Matthew Chung Yi Koh (ORCID: https://orcid.org/0009-0002-7374-8207)
- Jue Tao Lim (ORCID: https://orcid.org/0000-0002-2245-0331)
- Kelvin Bryan Tan
- LiangEn Wee
- An Ting Tay
- Enoch Xueheng Loy
- Phyllis Kim
- David Chien Boon Lye
- Calvin J Chiew
Institutions
- Agency for Science, Technology and Research (SG)
- Ministry of Health (SG)
- National Environment Agency (SG)
- National University of Singapore (SG)
- Nanyang Technological University (SG)
- Singapore General Hospital (SG)
- National University Health System (SG)
- National Centre for Infectious Diseases (SG)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2026-01-25
- DOI
- https://doi.org/10.1016/j.ijid.2026.108435
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Medical Research Council